



مركز الكويت لمكافحة السرطان
Kuwait Cancer Control Center

PAZOpanib (Votrient®)



Ministry of Health

Name:

File #:

Ht (cm):

Nationality:

Civil ID:

Wt (Kg):

Gender/Age:

DOB:

BSA (m²):

Indication(s): Advanced Soft Tissue Sarcoma after failure of chemotherapy (Not in liposarcoma)
 Metastatic renal cell carcinoma

Central line: Available NA

Allergies: NKA Yes, specify; _____

Parameters: Initiate treatment only if ANC \geq 1000; HB \geq 75; Plt \geq 100,000; CrCl $>$ 45 ml/min.

Standard Protocol:

DRUG	DOSE	ADMINISTRATION
PAZOpanib	60 800 mg PO once daily	To be given at least 1hr before or 2hr after a meal. Don't
To be given continuously until disease progression or intolerable toxicity.		

Special instructions: If PAZOpanib must be administered concomitantly with a potent enzyme inhibitor, reduce PAZOpanib to 400 mg PO once daily with careful monitoring; further dosage reductions may be needed if adverse events occur.

Treatment Description:

Cycle	Date	PAZOpanib	Physician	Consultant
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				

Important Notes:

Reported grade 3/4 toxicities: None Hematological Non-Hematological

If yes; Did it indicate hospitalization? Yes No

Did it indicate chemo-delay for \geq 7 days? Yes No

Did it indicate dose reduction? Yes No

Did it indicate G-CSF support? Yes No